A r t i c l e s
Cholangiocytes are the main site of dysfunction in cholangiopathies, a diverse group of bile duct disorders that includes inherited diseases such as CF-associated cholangiopathy, developmental diseases such as Alagille syndrome and autoimmune diseases such as primary biliary cirrhosis, as well as drug-and toxin-induced conditions 1 . Cholangiopathies carry significant morbidity and mortality, accounting for up to a third of adult and more than 70% of pediatric liver transplantations 2 . However, research on their pathophysiology has been limited by poor access to primary biliary tissue, difficulties in culturing primary cholangiocytes in vitro and inadequate animal disease models 3 .
The capacity of human induced pluripotent stem cells (hiPSCs) to proliferate indefinitely in culture and differentiate into a broad spectrum of cell types makes them well suited to in vitro disease modeling 4, 5 . Early methods for deriving cholangiocytes from hiPSCs 6 were based on spontaneous differentiation and had limited characterization of the resulting cells 7, 8 . Despite recent advances toward guided differentiation of hiPSCs to CLCs 9 , existing protocols show poor differentiation efficiency (<31%), and the derived cells differ considerably from primary biliary tissue in their transcriptional profiles. Furthermore, in vitro-generated cholangiocytes have not been shown to reproduce key functions of bona fide cholangiocytes, such as enzymatic activity (for example, alkaline phosphatase (ALP) and γ-glutamyl transferase (GGT)), responses to hormonal stimuli (secretin and somatostatin) and chloride transfer through cystic fibrosis transmembrane regulator (CFTR) activity [7] [8] [9] . Demonstration of these properties is essential for recapitulating cholangiopathies and studying the effects of therapeutic agents. Finally, current systems diverge from the physiological pathways controlling biliary development in vivo [7] [8] [9] , limiting their value for developmental studies.
Here we report a stepwise method for cholangiocyte differentiation that recapitulates native biliary development (Fig. 1a) . The quality, functionality and purity of the resulting CLCs are substantially higher than those of cells generated by previous methods (see Supplementary Note, Supplementary Methods and Supplementary Fig. 1 for detailed comparison).
RESULTS

Cholangiocyte progenitors generated from hiPSCs
We focused first on the generation of bipotent hepatoblasts, the common progenitor of hepatocytes and cholangiocytes 10 . To achieve this goal, cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation A r t i c l e s we adapted our established hepatic hiPSC differentiation protocol 11, 12 . Cells generated with the adapted protocol after 12 days of differentiation expressed hepatoblast markers, including α-fetoprotein (AFP), HNF4A, HNF1B, TBX3 and CK19 (KRT19) (Fig. 1b,d) , and had the potential to differentiate toward both the hepatic ( Supplementary  Fig. 2a-c) and biliary (Fig. 1c,d and Supplementary Table 1 ) lineages. To differentiate these hepatoblast-like cells into cholangiocyte progenitors (CPs), we interrogated pathways reported to control early biliary specification 10 ( Supplementary Fig. 3a-c and data not shown) and found that activin in combination with retinoic acid suppressed the expression of the hepatoblast markers AFP, HNF4A and TBX3 (Supplementary Fig. 3c ). Addition of fibroblast growth factor (FGF)-10 along with activin and retinoic acid induced the expression of the early biliary specification markers SOX9, HNF1B and CK19 (Fig. 1c,d ) 10 , resulting in a population in which 75.1% of cells were CK19 + Sox9 + (Supplementary Fig. 4a ). Flow cytometry analyses identified the majority of the remaining cells as Sox9 − AFP + hepatoblasts (Supplementary Fig. 4a ), explaining the presence of reduced but detectable levels of AFP in our culture (Fig. 1d) . Mature biliary markers such as secretin receptor (SCR, also known as SCTR), somatostatin receptor 2 (SSTR2), aquaporin1 (AQP1) and anion exchanger 2 (AE2, also known as SLC4A2) were not expressed (Fig. 1d) . Thus, activin, retinoic acid and FGF10 promote the differentiation of hepatoblast-like cells into early CLCs or CPs in vitro.
To promote maturation of the CPs, we used three-dimensional culture conditions known to induce cholangiocyte maturation through organoid formation [7] [8] [9] . CPs grown in these conditions proliferated rapidly, organized into ring-like structures after 48-72 h and within 5-7 d gave rise to cystic organoids and branching tubular structures (Fig. 2a,b ) bearing primary cilia (Fig. 2c ) similar to those of primary cholangiocytes. The organoids expressed biliary markers, including CK7 (KRT7), CK18 (KRT18), CK19, HNF1B, γ-glutamyl transferase (GGT1), Jagged1 (JAG1), NOTCH2, CFTR, SCR, SSTR2, AQP1 and AE2 (Figs. 1d and 2d) at levels similar to those in primary cholangiocytes ( Fig. 1d and  Supplementary Fig. 5 ). Transcriptomic analyses of common bile duct primary tissue and cells at key stages of our differentiation protocol ( Fig. 2e and Supplementary Table 2 ) using Euclidean hierarchical clustering revealed that CLCs are distinct from earlier developmental stages ( Fig. 2e and Supplementary Fig. 6 ), cluster closely with primary common bile duct cholangiocytes (Pearson correlation coefficient for CLCs versus primary cholangiocytes r = 0.747, CLCs versus hepatoblasts r = 0.576, CLCs versus hiPSCs: r = 0.474) and express both mature (SSTR2, ALPL, KRT7) and fetal (SOX9) biliary markers, as shown by immunofluorescence and quantitative PCR (QPCR) analyses ( Fig. 2e and Supplementary Fig. 6 ). These results confirm that CPs can differentiate into cells resembling biliary epithelial cells when grown in three-dimensional culture. 
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The efficiency of our differentiation protocol can be estimated from the observation that, by day 26, 1 × 10 6 hiPSCs produced 74.4 × 10 6 cells, of which 57.28 × 10 6 expressed mature biliary markers (74.4 × 10 6 cells generated × 77% (average differentiation efficiency across three lines, s.d. = 6.5%) = 57.28 × 10 6 CLCs) ( Supplementary Fig. 4a,b) . More specifically, 74.5% of the resulting cells expressed both the biliary marker Sox9 and the mature biliary marker CK7 ( Supplementary  Fig. 4a) . A further 7.5% of the cells, consistent with immature cholangiocytes, expressed Sox9 but not CK7 ( Supplementary Fig. 4a) ; 15% of the cells expressed both AFP and albumin (Supplementary Fig. 4a ), indicating the presence of a small fraction of hepatocytes in our culture conditions and explaining the detection of low AFP levels by QPCR analyses (Fig. 1d) . The remaining 3% of the cells were not characterized further. These results were confirmed on three independent hiPSC lines ( Supplementary Fig. 4a ).
Next we characterized the functionality of the generated organoids. In vivo, cholangiocytes reabsorb bile acids 13 and modify the composition of canalicular bile through a series of secretory and resorptive processes 14 regulated by intracellular calcium signaling 15 . Native biliary epithelial cells have ALP and GGT activity and proliferate in response to stimuli such as vascular endothelial growth factor (VEGF). The secretory potential of CLCs generated in vitro was confirmed using rhodamine 123, a fluorescent substrate for the cholangiocyte surface glycoprotein multidrug resistance protein-1 (MDR1) 16, 17 . Rhodamine 123 was actively secreted in the lumen of CLC organoids, and luminal dye accumulation was prevented by the MDR1 inhibitor verapamil (Fig. 3a-c) , confirming MDR1-dependent transfer of rhodamine 123. The capacity of CLCs to interact with bile acids through the apical salt and bile transporter (ASBT) 13 
)) (two-tailed t-test).
(j) CLC organoids exhibit GGT activity. MEF, mouse embryonic feeders; n = 3, P < 0.0001 for all comparisons (one-way ANOVA with Dunnett correction for multiple comparisons).
(k) ALP staining revealing ALP activity in CLC organoids. Top, photographs of stained wells. Scale bars, 1 cm. Bottom, brightfield microscopy images; n = 3. Boxed area is magnified in inset. Scale bars, 100 µm. Data representative of 3 lines (Fig. 6a,b and Supplementary Fig. 5 ). All error bars represent s.d. Asterisks (****) in panels c, f, h and j indicate statistical significance of the differences demonstrated (P < 0.0001).
( Fig. 3d-f and Supplementary Videos 1 and 2) . ASBT expression was confirmed by QPCR and immunofluorescence analyses ( Supplementary Fig. 7a,b) . Furthermore, CLCs responded to acetylcholine and ATP stimuli by increasing intracellular calcium ( Fig. 3g and Supplementary Videos 3 and 4), demonstrated increased proliferation in response to VEGF stimulation (51% increase in expansion, P < 0.0001, two-tailed t-test) (Fig. 3h,i) and exhibited GGT and ALP activities similar to those of primary controls (GGT activity: 160% of human serum activity, P < 0.0001, one-way ANOVA with Dunnett correction for multiple comparisons) (Fig. 3j,k) . Together, these observations confirm that our hiPSC-derived CLCs display a range of functions of the native biliary epithelium.
CLCs model development of the human biliary system
To investigate potential applications of our system for developmental studies, we characterized signaling pathways that control organoid formation in vitro as compared with native duct development. First, we interrogated activin-TGF-β signaling in view of its pivotal role in physiological biliary specification and tubulogenesis 10, 18, 19 . We blocked the activity of TGF-β, which is normally present in Matrigel, using the activin receptor inhibitor SB-431542. SB-431542 completely abrogated organoid formation (Fig. 4a,b) ,
confirming that activin-TGF-β signaling is a key regulator of organoid formation in our system. We performed similar analyses for Notch signaling during biliary specification of hepatoblasts to CPs and CLC organoid formation in vitro. Deregulation of Notch signaling is associated with Alagille syndrome, characterized by a paucity of bile ducts 20 . To explore the hypothesis that blocking Notch signaling would impair organoid formation in vitro, we first characterized the activity of the Notch pathway in our system. Notch activation results in cleavage and nuclear translocation of its intracellular domain [21] [22] [23] . Immunofluorescence analysis with antibodies specific to the cleaved Notch intracellular domain (NICD) confirmed the presence of active NICD, with increased nuclear localization in CPs (Supplementary Fig. 8 ) and CLC organoids (Fig. 4d) . The expression of NOTCH2, as well as its ligand JAG1 and its downstream target HES1, were also increased in both stages compared to hepatoblasts, consistent with pathway activation (CPs versus hepatoblasts: NOTCH2, P < 0.001; JAG1, P < 0.001; HES1, P < 0.05; CLCs versus CPs or hepatoblasts: P < 0.0001, one-way ANOVA with Tukey correction for multiple comparisons) (Fig. 1d) . Inhibition of Notch signaling in three-dimensional culture conditions using the γ-secretase inhibitor L-685,458 blocked cleavage of the NICD, suppressed HES1, NOTCH2 and JAG1 (Fig. 4c) and blocked organoid formation (Fig. 4e,f) , confirming the importance of Notch signaling to the generation of organoids incorporating a luminal space in our system. These results reinforce previous findings obtained in mice by demonstrating the importance of activin-TGF-β and Notch signaling pathways in human cholangiocyte specification 24 . They underline the potential of our culture system for studying human biliary tree development in vitro.
CLCs validate drugs for polycystic liver diseases Polycystic liver diseases are characterized by multiple cystic lesions in the liver arising from fetal cholangiocytes 25, 26 . Intraluminal fluid secretion and cholangiocyte proliferation result in cyst expansion and liver impairment owing to space-occupying effects 27, 28 . We explored the use of CLC organoids to identify compounds that might reduce cyst size in polycystic liver disease. The secretory activity of cholangiocytes is increased by the hormone secretin and reduced by the hormone somatostatin, resulting in changes in duct size. Octreotide, a synthetic analog of somatostatin, is used clinically to restrict cyst size in polycystic liver disease [28] [29] [30] [31] [32] . CLC organoids express both SCR and SSTR2 (Figs. 1d and 5a,b) , suggesting that these pathways may be functional in our cells. Accordingly, secretin increased organoid size (6.1% average diameter increase, P < 0.01, one-way ANOVA with Dunnett correction for multiple comparisons), whereas somatostatin and octreotide decreased organoid size, compared to untreated controls (7.9% and 4.9% average diameter decrease, respectively; P < 0.001 and P < 0.05, respectively; one-way ANOVA with Dunnett correction for multiple comparisons) (Fig. 5c,d and Supplementary Videos 5-7) .
Furthermore, octreotide negated the effects of secretin and decreased intracellular cyclic AMP (45% of somatostatin response; P = 0.001, one-way ANOVA with Dunnett correction for multiple comparisons), in keeping with previous studies 26, 30 (Fig. 5e) . To further test the effects of octreotide on disease-specific CLCs, we differentiated hiPSCs derived from a patient with polycystic liver disease (Supplementary Fig. 9 ) to CLCs (Fig. 5f) . Octreotide treatment reduced organoid size (4.86%, P < 0.0001, one-way ANOVA with Dunnett correction for multiple comparisons) (Fig. 5g,h) , reproducing the effects of the drug in vitro.
CLCs model CF liver disease
The autosomal recessive disorder CF is caused by mutations in the CFTR gene, encoding a cell-surface chloride transporter 33, 34 . CFTR mutations in cholangiocytes result in reduced intraluminal chloride secretion, increased bile viscosity and focal biliary cirrhosis secondary to bile plugs occluding the intrahepatic bile ducts [35] [36] [37] . To model CF biliary disease in vitro, we generated hiPSCs from skin fibroblasts of a patient homozygous for the most common CF mutation, ∆F508 (CF-hiPSCs) 38 , and differentiated them into CLCs. CF-hiPSC-derived CLCs (CF-CLCs) expressed markers ( Fig. 6a) and displayed functional characteristic (Fig. 6b) of biliary epithelial cells. Transcription of the CFTR gene was confirmed using QPCR (Fig. 6a) , and immunofluorescence analyses detected minimal CFTR protein expression (Fig. 6c) , in agreement with studies reporting very rapid endoplasmic reticulum degradation of the misfolded protein 39 . We also used the fluorescent chloride indicator N-(6-methoxyquinolyl)acetoethyl ester (MQAE) 40 to monitor intracellular and intraluminal chloride 
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Next we investigated the effects of the experimental CF drug VX809 (ref. 41) in the context of biliary disease. VX809 stabilizes CFTR, corrects folding defects in patients with the ∆F508 mutation and increases CFTR functionality in lung cells 42 
. Incubation of CF-CLCs with VX809
for 48 h increased CFTR function analyzed by MQAE to a level similar to that of WT-CLCs (Fig. 6d,e) . This effect was negated by CFTR inhibitor 172, confirming that the phenotypic rescue of CF-CLCs by VX809 depended on improved CFTR function (Fig. 6d,e) . Given the association between chloride and fluid secretion in cholangiocytes 33 , we studied the impact of VX809 on organoid size. CF-CLC organoids treated with VX809 increased in size compared to their untreated counterparts (5.6% mean diameter increase, P = 0.001, two-tailed t-test) (Fig. 6f,g ). This observation confirmed that VX809 increases CFTR function and improves intraluminal fluid secretion, suggesting a previously unreported therapeutic effect for this drug in the context of CF liver disease.
DISCUSSION
We present a protocol for the generation of CLCs from hiPSCs that addresses the limitations of previously published differentiation methods by more closely recapitulating natural bile duct development (Fig. 1a) . Our results confirm the importance of FGF10 and activin-TGF-β for early biliary specification, as previously described in vivo 10, 19, 43 , and reveal a role for retinoic acid in this process, at least in vitro. We show that the combination of these factors under chemically defined, serum-free conditions is sufficient to promote the specification of hiPSC-derived hepatoblasts into CPs with high efficiency. Production of CPs, mimicking physiological biliary development, has not been demonstrated previously, to our knowledge, and likely explains the efficiency of our culture system in generating CLCs that closely resemble bona fide cholangiocytes at the transcriptional ( Supplementary Fig. 1 and Supplementary Tables 3 and 4) and functional (Supplementary Table 3 ) levels.
Our protocol will enable various applications, such as developmental studies, disease modeling, therapeutic target validation and drug screening. Accordingly, we used patient-derived hiPSCs to model polycystic and CF liver disease and applied these models to reproduce the effects of the therapeutic compounds verapamil, octreotide and VX809. VX809 has already completed phase 2a clinical trials 42 for CF, but its effects on CF-associated cholangiopathy have not been described, to our knowledge. Our results suggest that CLCs provide a suitable system for identifying new therapeutic agents, which is particularly 
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A r t i c l e s important given the lack of high-throughput drug screening platforms for cholangiopathies. CLCs may also contribute to tissue engineering of livers or liver organoids that incorporate a biliary system for the treatment of end-stage disease.
METHODS
Methods and any associated references are available in the online version of the paper.
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The authors would like to thank the Cambridge BRC hiPSCs core facility for the derivation of the cystic fibrosis hiPSC line, P. 1 µM dexamethasone (R&D Systems), 2 mM Glutamax (Invitrogen), 100 U/ml penicillin, 100 µg/ml streptomycin and 20 ng/ml EGF (R&D Systems). A 50-µL droplet of the cell suspension was added in the center of each well of a 24-well plate; the gel was allowed 1 h at 37 °C to solidify and then overlaid with William's E medium with supplements. The medium was changed every 48 h and the cells were cultured for a total of 10 d. Using the same methodology, we have been able to culture CLC organoids in formats ranging from 6-to 96-well plates. To generate large numbers of CLC organoids, multiple 50-µL droplets were added in a well of a 6-well plate or a 10-cm dish. To provide a large number of wells compatible with high-throughput screening and large-scale experiments, 30-µL droplets were added per well of a 96-well plate. In both cases, the gel was allowed 1 h at 37 °C to solidify and then overlaid with William's E medium with supplements.
Inhibition of activin and Notch signaling in 3D culture and assessment of organoid formation. Human CPs were suspended at a density of 8 × 10 4 cells/ml, in a mixture of 40% Matrigel and 60% William's E medium (Gibco, Life Technologies) with supplements as described above. The cell suspension was distributed in three aliquots of equal volume. One aliquot received no further supplementation and was used as a positive control. The second aliquot was further supplemented by 10 µM SB-431542 for the inhibition of activin-TGF-β signaling. 50 µM L-685,458 (Tocris Biosciences) was added in the third aliquot for the inhibition of Notch signaling. Each aliquot was distributed in 24-well-plate format. The same concentrations of inhibitors were added to the medium overlaying the Matrigel on a daily basis. After a total of 10 d in 3D culture, the total number of cysts in four random wells of a 24-well plate was counted for each condition by a researcher blinded to sample identity. Error bars represent s.d.
Flow cytometry analyses.
HiPSCs, FPs, HBs and CPs were dissociated to single cells using Cell Dissociation Buffer (Life Technologies). The cells were then counted using a hemocytometer and fixed using 4% PFA for 20 min at 4 °C. Cell staining and flow cytometry analyses were performed as previously described 44 .
CLC organoids were washed once with PBS and 1 ml of ice-cold dispase was added per well of a 24-well plate. The Matrigel was mechanically dissociated, transferred to a Falcon tube and kept on ice to allow the combination of low temperature and dispase digestion to liquefy the Matrigel. After 10 min the cells were centrifuged at 1,600 r.p.m. (444g) for 3 min and the supernatant was aspirated. The pellet was washed once with PBS and the centrifugation step repeated. The supernatant was aspirated and 1 ml of TrypLE (Life Technologies) was added for 3-5 min until the organoids were dissociated to single cells. Finally, the single cell suspension was centrifuged at 1,600 r.p.m. (13.2g) for 3 min, and fixed using 4% PFA for 20 min at 4 °C. Cell staining and flow cytometry analyses were performed as previously described 44 .
Primary cholangiocytes. Frozen primary human cholangiocytes derived from common bile duct were obtained from Celprogen (catalog number 36755-11). The cells were derived from donors negative for hepatitis B surface antigen, HIV 1 and 2, syphilis, hepatitis B virus, human T lymphotropic viruses 1 and 2, hepatitis C virus, West Nile virus and Trypanosoma cruzi. Each frozen ampule (1.2 × 10 6 cells) of 1 × 10 6 viable cells was thawed with gentle agitation in a 37 °C water bath. The cells were transferred to a sterile centrifuge tube and 1 ml of prewarmed Human Cholangiocyte Cell Culture Complete Growth Medium (Celprogen, catalog number M36755-11S) was added. The ampule was washed twice with Human Cholangiocyte Cell Culture Complete Growth Medium and the cells were centrifuged at 100g for 7 min. The pellet was resuspended in 500 µl of Human Cholangiocyte Cell Culture Complete Growth Medium. The cells were distributed equally to two wells of a 6-well plate precoated with Human Cholangiocyte Cell Culture Extracellular Matrix Celprogen, catalog number M36755-11-6-wells) with 2 ml of Human Cholangiocyte Cell Culture Complete Growth Medium per well. The cells were incubated at 37 °C in a 5% CO 2 , humidified incubator for 48 h and the medium was changed once. After another 24 h, when the wells were confluent, the cells were lysed and RNA was extracted as previously described 11, 12 , or the cells were fixed with 4% PFA as previously described 11, 12 for ALP staining. QPCR analyses for biliary markers (Fig. 1d) and ALP staining (Fig. 3k) confirmed the nature and cholangiocyte properties of the cells.
Primary biliary tissue.
Primary biliary tissue (bile duct) was obtained from an organ donor from whom organs were being retrieved for transplantation. A section of the bile duct was excised during the multi-organ retrieval operation after obtaining informed consent from the donor's family (REC reference number: 09/H0306/73, NRES Committee East of England-Norfolk). The tissue was homogenized using a tissue homogenizer and RNA was extracted as previously described 11 .
Immunofluorescence, RNA extraction and quantitative real-time PCR. Immunofluorescence, RNA extraction and QPCR were performed as previously described 9 . A complete list of the primary and secondary antibodies used is provided in Supplementary Table 5 . A complete list of the primers used is provided in Supplementary Table 6. All QPCR data correspond to four independent biological replicates, with the exception of the primary CDB cholangiocytes from Celprogen, where three independent samples were used.
For immunofluorescence in 3D Matrigel cultures, the organoids were fixed in Matrigel with 4% PFA for 20 min at room temperature, to avoid Matrigel liquefaction. The samples were permeabilized and blocked with 0.1% Triton X-100 and 10% donkey serum respectively for 30 min and incubated with primary antibody in 1% donkey serum overnight at 4 °C. The following day the samples were washed three times with PBS for 45 min per wash, incubated with secondary antibody in 1% donkey serum for 60 min at room temperature and washed again three times in PBS. Hoechst 33258 was added to the first wash.
All immunofluorescence images were acquired using a Zeiss Axiovert 200M inverted microscope or a Zeiss LSM 700 confocal microscope. ImageJ 1.48k software (Wayne Rasband, NIHR, USA, http://imagej.nih.gov/ij) was used for image processing. Changes in brightness or contrast during processing were applied equally across the entire image.
For RNA extraction in 3D Matrigel cultures, the organoids were washed once with PBS and 1 ml of ice-cold dispase was added per well of a 24-well plate.
